AR067977A1 - DERIVATIVES OF PIRIDINE AND ITS USE AS IMMUNOMODULATORS - Google Patents
DERIVATIVES OF PIRIDINE AND ITS USE AS IMMUNOMODULATORSInfo
- Publication number
- AR067977A1 AR067977A1 ARP080103611A ARP080103611A AR067977A1 AR 067977 A1 AR067977 A1 AR 067977A1 AR P080103611 A ARP080103611 A AR P080103611A AR P080103611 A ARP080103611 A AR P080103611A AR 067977 A1 AR067977 A1 AR 067977A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- compound
- methoxy
- attached
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Dichos compuestos actuan particularmente como agentes inmunomoduladores. Reivindicacion 1: Un compuesto de formula (1), Piridina1-A-Piridiria2, donde Piridina1 representa un compuesto del grupo de formulas (2) donde los asteriscos marcan el enlace con el cual el anillo de Piridina1 está unido a A; R1 representa alquilo C1-5, alcoxi C1-4, cicloalquilo C3-6, hidroximetilo, o NR1aR1b; R1a representa alquilo C1-4, R1b representa hidrogeno, o alquilo C1-3, o R1a y R1b, junto con el nitrogeno que está unido a la piridina, forman un anillo de pirrolidina; R2 representa hidrogeno, o alquilo C1-4, o en el caso en que R1 represente alquilo C1-5 o cicIoalquilo C3-6, R2 puede representar además rnetoxi; R3 representa alquilo C1-5, alcoxi C1-4, cicloalquilo C3-6, o NR3aR3b; R3a representa alquilo C1-4; R3b representa H, o alquilo C1-3; R4 representa alquilo C1-4, o H; R5 representa alquilo C1-5, metoxi, o NR5aR5b; y R6 representa alquilo C1-2; R5a representa alquilo C1-4; R5b representa H, o alquilo C1-3; o R5 representa alquilo C1-2, o metoxi; y R6 representa alquilo C1-5, o NR6aR6b; R6a representa alquilo C1-4; R6b representa hidrogeno, o alquilo C1-3; R7 representa alquilo C1-5; R8 representa alquilo C1-2, o metoxi; R9 representa alquilo C1-5; R10 representa alquilo C1-2; A representa un compuesto del grupo de las formulas (3), donde los asteriscos indican el enlace que está unido al anillo de Piridina1; Piridina2 representa un compuesto del grupo de formulas (4), donde los asteriscos marcan el enlace con el cual el anillo de Piridina2 está unido a A; R11 representa alquilo C1-4, alcoxi C1-3, hidroximetilo, o NR11aR11b; R11a representa alquilo C1-3, R11b representa hidrogeno, o alquilo C1-2, R12 representa hidrogeno, o alquilo C1-2, R13 representa alquilo C1-4, o representa NR13aR13b; R13a representa alquilo C1-3; R13b representa hidrogeno, o alquilo C1-2, R14 representa alquilo C1-2; R15 representa alquilo C1-4, o NR15aR15b; y R16 representa alquilo C1-2; R15a representa alquilo C1-3, R15b representa hidrogeno, o alquilo C1-3; o R15 representa alquilo C1-2; y R16 representa alquilo C1-4, o NR16aR16b; R16a representa alquilo C1-3; R16b representa hidrogeno, o alquilo C1-2; R17 representa alquilo C1-4; R18 representa alquilo C1-2, o metoxi; R19 representa alquilo C1-4; y R20 representa alquilo C1-2; con la excepcion de 3-(2-etil-4-piridil)-5-(2-etil-4-piridil)-1,2,4-oxadiazol; o una sal de dicho compuesto.Such compounds act particularly as immunomodulating agents. Claim 1: A compound of formula (1), Pyridine1-A-Pyridyria2, wherein Pyridine1 represents a compound of the group of formulas (2) wherein the asterisks mark the bond with which the ring of Pyridine1 is attached to A; R1 represents C1-5 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, hydroxymethyl, or NR1aR1b; R1a represents C1-4 alkyl, R1b represents hydrogen, or C1-3 alkyl, or R1a and R1b, together with the nitrogen that is attached to pyridine, form a pyrrolidine ring; R2 represents hydrogen, or C1-4 alkyl, or in the case where R1 represents C1-5 alkyl or C3-6 cycloalkyl, R2 may further represent rnethoxy; R3 represents C1-5 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, or NR3aR3b; R3a represents C1-4 alkyl; R3b represents H, or C1-3 alkyl; R4 represents C1-4 alkyl, or H; R5 represents C1-5 alkyl, methoxy, or NR5aR5b; and R6 represents C1-2 alkyl; R5a represents C1-4 alkyl; R5b represents H, or C1-3 alkyl; or R5 represents C1-2 alkyl, or methoxy; and R6 represents C1-5 alkyl, or NR6aR6b; R6a represents C1-4 alkyl; R6b represents hydrogen, or C1-3 alkyl; R7 represents C1-5 alkyl; R8 represents C1-2 alkyl, or methoxy; R9 represents C1-5 alkyl; R10 represents C1-2 alkyl; A represents a compound of the group of formulas (3), where the asterisks indicate the bond that is attached to the pyridine ring1; Pyridine2 represents a compound of the group of formulas (4), where the asterisks mark the link with which the Pyridine2 ring is attached to A; R11 represents C1-4 alkyl, C1-3 alkoxy, hydroxymethyl, or NR11aR11b; R11a represents C1-3 alkyl, R11b represents hydrogen, or C1-2 alkyl, R12 represents hydrogen, or C1-2 alkyl, R13 represents C1-4 alkyl, or represents NR13aR13b; R13a represents C1-3 alkyl; R13b represents hydrogen, or C1-2 alkyl, R14 represents C1-2 alkyl; R15 represents C1-4 alkyl, or NR15aR15b; and R16 represents C1-2 alkyl; R15a represents C1-3 alkyl, R15b represents hydrogen, or C1-3 alkyl; or R15 represents C1-2 alkyl; and R16 represents C1-4 alkyl, or NR16aR16b; R16a represents C1-3 alkyl; R16b represents hydrogen, or C1-2 alkyl; R17 represents C1-4 alkyl; R18 represents C1-2 alkyl, or methoxy; R19 represents C1-4 alkyl; and R20 represents C1-2 alkyl; with the exception of 3- (2-ethyl-4-pyridyl) -5- (2-ethyl-4-pyridyl) -1,2,4-oxadiazole; or a salt of said compound.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2007053293 | 2007-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067977A1 true AR067977A1 (en) | 2009-10-28 |
Family
ID=40193868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103611A AR067977A1 (en) | 2007-08-17 | 2008-08-19 | DERIVATIVES OF PIRIDINE AND ITS USE AS IMMUNOMODULATORS |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8598208B2 (en) |
| EP (1) | EP2195311B1 (en) |
| JP (1) | JP5451614B2 (en) |
| KR (1) | KR101541558B1 (en) |
| CN (1) | CN102648198B (en) |
| AR (1) | AR067977A1 (en) |
| AT (1) | ATE502938T1 (en) |
| AU (1) | AU2008290233B2 (en) |
| BR (1) | BRPI0815190A2 (en) |
| CA (1) | CA2695509A1 (en) |
| CY (1) | CY1111830T1 (en) |
| DE (1) | DE602008005770D1 (en) |
| DK (1) | DK2195311T3 (en) |
| ES (1) | ES2361463T3 (en) |
| HK (1) | HK1144809A1 (en) |
| HR (1) | HRP20110449T1 (en) |
| MA (1) | MA31703B1 (en) |
| MX (1) | MX2010001881A (en) |
| MY (1) | MY153975A (en) |
| NZ (1) | NZ583957A (en) |
| PL (1) | PL2195311T3 (en) |
| PT (1) | PT2195311E (en) |
| RU (1) | RU2492168C2 (en) |
| SI (1) | SI2195311T1 (en) |
| TW (1) | TWI422373B (en) |
| WO (1) | WO2009024905A1 (en) |
| ZA (1) | ZA201001873B (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007292993B2 (en) * | 2006-09-07 | 2013-01-24 | Idorsia Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
| ES2400163T3 (en) | 2006-09-08 | 2013-04-08 | Actelion Pharmaceuticals Ltd. | Pyridyl-3-yl derivatives as immunomodulation agents |
| EP2079734A1 (en) * | 2006-10-25 | 2009-07-22 | NeuroSearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| CA2679138C (en) * | 2007-03-16 | 2015-05-26 | Actelion Pharmaceuticals Ltd | Amino-pyridine derivatives as s1p1/edg1 receptor agonists |
| PL2252609T3 (en) * | 2008-03-07 | 2013-09-30 | Idorsia Pharmaceuticals Ltd | Pyridin-2-yl derivatives as immunomodulating agents |
| EP2278960B2 (en) | 2008-03-17 | 2019-11-13 | Actelion Pharmaceuticals Ltd. | Dosing regimen for a selective sip1 receptor agonist |
| PT2427416E (en) | 2009-05-04 | 2016-06-15 | Prometic Pharma Smt Ltd | Substituted aromatic compounds and pharmaceutical uses thereof |
| ES2441845T3 (en) | 2009-07-16 | 2014-02-06 | Actelion Pharmaceuticals Ltd. | Pyridin-4-yl derivatives as S1P1 / EDG1 agonists |
| EP2665720B1 (en) | 2011-01-19 | 2015-06-10 | Actelion Pharmaceuticals Ltd. | 2-methoxy-pyridin-4-yl derivatives |
| EP2844655A1 (en) | 2012-05-02 | 2015-03-11 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| PT2885266T (en) | 2012-08-17 | 2020-05-29 | Actelion Pharmaceuticals Ltd | Process for the preparation of!(2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-!(o-tolyl)thiazolidin-4-one and intermediate used in said process |
| ES2649475T3 (en) | 2013-03-15 | 2018-01-12 | Idorsia Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
| MX2017014846A (en) | 2015-05-20 | 2018-02-19 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-met hoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-pheno xy}-propane-1,2-diol. |
| US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
| WO2017004608A1 (en) | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Oxadiazole modulators of s1p methods of making and using |
| WO2017004610A1 (en) | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Tercyclic s1p3-sparing, s1p1 receptor agonists |
| WO2017004609A1 (en) | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Thiadiazole modulators of s1p and methods of making and using |
| CN109069514B (en) | 2016-03-07 | 2023-12-29 | 结核病药物开发全球联盟公司 | Antibacterial compound and application thereof |
| BR112018068681A2 (en) | 2016-03-16 | 2019-01-15 | Bayer Cropscience Ag | n- (cyanobenzyl) -6- (cyclopropylcarbonylamino) -4- (phenyl) pyridine-2-carboxamide derivatives and related compounds as pesticides and plant protection agents |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US20240018106A1 (en) * | 2020-09-11 | 2024-01-18 | Pi Industries Ltd. | A process for the preparation of substituted pyridine compounds and intermediates thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3647809A (en) * | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| AU7686891A (en) | 1990-04-05 | 1991-10-30 | American National Red Cross, The | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
| US6423508B1 (en) | 1998-03-09 | 2002-07-23 | Smithkline Beecham Corporation | Polynucleotide sequences of human EDG-1c |
| KR100875222B1 (en) | 1999-08-19 | 2008-12-19 | 아스트라제네카 아베 | Heteropolycyclic Compounds and Their Uses as Indirect Glutamate Receptor Antagonists |
| ATE375340T1 (en) | 2001-02-21 | 2007-10-15 | Nps Pharma Inc | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMA RECEPTOR ANTAGONISTS |
| AU2003202994B2 (en) | 2002-01-18 | 2007-11-22 | Merck Sharp & Dohme Corp. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists |
| AU2003207567B2 (en) | 2002-01-18 | 2008-01-24 | Merck Sharp & Dohme Corp. | Edg receptor agonists |
| AU2003279915A1 (en) | 2002-10-15 | 2004-05-04 | Merck And Co., Inc. | Process for making azetidine-3-carboxylic acid |
| CN1788008A (en) * | 2003-05-15 | 2006-06-14 | 麦克公司 | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists |
| CA2539438A1 (en) * | 2003-10-01 | 2005-04-14 | Merck And Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| WO2005058848A1 (en) * | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| KR20070045153A (en) | 2004-05-29 | 2007-05-02 | 7티엠 파마 에이/에스 | Crth2 receptor ligands for medicinal uses |
| JP4521463B2 (en) | 2005-03-17 | 2010-08-11 | ファイザー株式会社 | N- (N-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain |
| ATE477253T1 (en) | 2005-04-26 | 2010-08-15 | Neurosearch As | NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE |
| BRPI0612028A2 (en) | 2005-06-08 | 2010-10-13 | Novartis Ag | polycyclic oxadiazoles or isodiazoles and their use as s1p receptor ligands |
| US20090054491A1 (en) | 2005-06-28 | 2009-02-26 | Astrazeneca Ab | Use |
| TWI404706B (en) * | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | Novel thiophene derivatives |
| CA2635124C (en) | 2006-01-24 | 2014-04-29 | Actelion Pharmaceuticals Ltd | Novel pyridine derivatives |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| AU2007292993B2 (en) | 2006-09-07 | 2013-01-24 | Idorsia Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
| ES2400163T3 (en) | 2006-09-08 | 2013-04-08 | Actelion Pharmaceuticals Ltd. | Pyridyl-3-yl derivatives as immunomodulation agents |
| EP2069318B1 (en) | 2006-09-21 | 2012-09-12 | Actelion Pharmaceuticals Ltd. | Phenyl derivatives and their use as immunomodulators |
| US7834039B2 (en) | 2006-12-15 | 2010-11-16 | Abbott Laboratories | Oxadiazole compounds |
| CA2679138C (en) | 2007-03-16 | 2015-05-26 | Actelion Pharmaceuticals Ltd | Amino-pyridine derivatives as s1p1/edg1 receptor agonists |
| NZ585775A (en) | 2007-11-01 | 2011-12-22 | Actelion Pharmaceuticals Ltd | Novel pyrimidine derivatives |
| WO2009109907A1 (en) | 2008-03-06 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel pyrimidine-pyridine derivatives |
| CN101965345B (en) | 2008-03-06 | 2014-05-28 | 埃科特莱茵药品有限公司 | Pyridine compounds |
| AU2009220893A1 (en) | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel aminomethyl benzene derivatives |
| PL2252609T3 (en) | 2008-03-07 | 2013-09-30 | Idorsia Pharmaceuticals Ltd | Pyridin-2-yl derivatives as immunomodulating agents |
| EP3782991A1 (en) | 2008-05-14 | 2021-02-24 | The Scripps Research Institute | Novel modulators of sphingosine phosphate receptors |
| ES2441845T3 (en) | 2009-07-16 | 2014-02-06 | Actelion Pharmaceuticals Ltd. | Pyridin-4-yl derivatives as S1P1 / EDG1 agonists |
-
2008
- 2008-08-14 EP EP08789611A patent/EP2195311B1/en not_active Not-in-force
- 2008-08-14 DE DE602008005770T patent/DE602008005770D1/en active Active
- 2008-08-14 PT PT08789611T patent/PT2195311E/en unknown
- 2008-08-14 ES ES08789611T patent/ES2361463T3/en active Active
- 2008-08-14 DK DK08789611.4T patent/DK2195311T3/en active
- 2008-08-14 CA CA2695509A patent/CA2695509A1/en not_active Abandoned
- 2008-08-14 AT AT08789611T patent/ATE502938T1/en active
- 2008-08-14 JP JP2010520670A patent/JP5451614B2/en not_active Expired - Fee Related
- 2008-08-14 MY MYPI2010000684A patent/MY153975A/en unknown
- 2008-08-14 PL PL08789611T patent/PL2195311T3/en unknown
- 2008-08-14 NZ NZ583957A patent/NZ583957A/en not_active IP Right Cessation
- 2008-08-14 CN CN200880103070.2A patent/CN102648198B/en not_active Expired - Fee Related
- 2008-08-14 RU RU2010109542/04A patent/RU2492168C2/en not_active IP Right Cessation
- 2008-08-14 SI SI200830269T patent/SI2195311T1/en unknown
- 2008-08-14 MX MX2010001881A patent/MX2010001881A/en active IP Right Grant
- 2008-08-14 AU AU2008290233A patent/AU2008290233B2/en not_active Ceased
- 2008-08-14 WO PCT/IB2008/053269 patent/WO2009024905A1/en active Application Filing
- 2008-08-14 BR BRPI0815190 patent/BRPI0815190A2/en not_active IP Right Cessation
- 2008-08-14 KR KR1020107005759A patent/KR101541558B1/en not_active IP Right Cessation
- 2008-08-14 US US12/673,918 patent/US8598208B2/en not_active Expired - Fee Related
- 2008-08-15 TW TW097131346A patent/TWI422373B/en not_active IP Right Cessation
- 2008-08-19 AR ARP080103611A patent/AR067977A1/en not_active Application Discontinuation
-
2010
- 2010-03-12 MA MA32693A patent/MA31703B1/en unknown
- 2010-03-16 ZA ZA2010/01873A patent/ZA201001873B/en unknown
- 2010-12-03 HK HK10111281.3A patent/HK1144809A1/en not_active IP Right Cessation
-
2011
- 2011-05-30 CY CY20111100521T patent/CY1111830T1/en unknown
- 2011-06-16 HR HR20110449T patent/HRP20110449T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067977A1 (en) | DERIVATIVES OF PIRIDINE AND ITS USE AS IMMUNOMODULATORS | |
| AR059494A1 (en) | BISAMIDE BICYCLE DERIVATIVES WITH PESTICIATED ACTIVITY | |
| AR070801A1 (en) | PYRIMIDIN-PYRIDINE DERIVATIVES | |
| EA200600925A1 (en) | DERIVATIVES OF TRIAZOLE AS ANTAGONISTS VAZOPRESSIN | |
| AR079224A1 (en) | INSECTICIDE COMPOUNDS BASED ON ISOXAZOLINE DERIVATIVES | |
| JO3088B1 (en) | Macrocyclic Quinazoline derivatives and their use as MTKI | |
| TR200201752T2 (en) | Dipeptide nitrile cathepsin K inhibitors. | |
| PE20090042A1 (en) | CYCLOPAMINE ANALOGS | |
| AR041182A1 (en) | DERIVATIVES OF PHENOXIPROPENYLPHENYL AND ITS USE AS HERBICIDES | |
| PE20050265A1 (en) | DERIVATIVES OF ALKYLARYL ACID AS INHIBITORS OF DIACILGLICEROL ACYLTRANSFERASE TYPE 1 (DGAT-1) | |
| DK1533292T3 (en) | Dibenzylamine compound and its medical use | |
| ATE506354T1 (en) | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDE AS GLUCOCINASE ACTIVATORS | |
| CO5700774A2 (en) | TRIAZOL DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASA-1 | |
| AR059178A1 (en) | BENZOTIAZOLES HETEROARIL REPLACED, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THERAPEUTIC USES, BETWEEN THEM, IN THE TREATMENT AND / OR PREVENTION OF ALZHEIMER'S DISEASE. | |
| ES2330313T3 (en) | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST INFECTION WITH FLAVIVIRUS. | |
| MX2007000035A (en) | Cetp inhibitors. | |
| DOP2010000046A (en) | SUBSTITUTED BICYCOLACTAMA COMPOUNDS | |
| AR076694A1 (en) | BENZOXAZEPINAS AS INHIBITORS OF PI3K / M / TOR, ITS USE IN THE TREATMENT OF CANCER AND ITS PREPARATION | |
| AR067327A1 (en) | PIPERIDINE / PIPERAZINE DERIVATIVES | |
| AR083953A1 (en) | COMPOUNDS TO TREAT NEURODEGENERATIVE DISEASES | |
| AR038377A1 (en) | DERIVATIVES OF N-BIFENIL-AMINOCICLOALCANCARBOXAMIDA (WITH REPLACEMENT WITH METHYL) | |
| AR070463A1 (en) | AMINA AND ETER COMPOUNDS THAT MODULATE THE CB2 RECEIVER | |
| AR078775A1 (en) | PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AN INDOL COMPOUND | |
| AR074902A1 (en) | DERIVATIVES OF 1,2,4-OXADIAZOLS AGONISTS OF RECEIVERS S1P1 | |
| AR037907A1 (en) | DERIVATIVES OF AZAINDOLILALQUILAMINA AS 5-HYDROXYTHYRIPTAMINE-6 LIGANDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |